Per-Henrik Nilsson

Learn More
BACKGROUND Tumefactive demyelinating disease (TDD) is a rare primary demyelinating disease with diagnostic and therapeutic challenges. METHODS AND RESULTS We report a 50-year old woman with TDD successfully treated with decompressive craniectomy and corticosteroids. The patient presented with seizures, subacute progressive hemispheric syndrome, and a(More)
BACKGROUND The resource use and health-related quality of life (HRQoL) of patients with multiple sclerosis (MS) spasticity are not well known. The purpose of this study was to obtain estimates of resource utilization, costs, and HRQoL, for patients with different levels of MS spasticity in southern Sweden. MATERIAL AND METHODS Cross-sectional data on(More)
The clinical applicability of the revised McDonald diagnostic criteria of primary progressive multiple sclerosis (PPMS) was assessed in 17 patients with a longstanding PPMS diagnosis (mean 15 years). All patients were re-evaluated with clinical examinations, magnetic resonance imaging (MRI) of the brain and the spinal cord, extensive laboratory tests, and(More)
Multiple sclerosis (MS) is associated with inflammatory lesions in the brain and spinal cord. The detection of such inflammatory lesions using magnetic resonance imaging (MRI) is important in the consideration of the diagnosis and differential diagnoses of MS, as well as in the monitoring of disease activity and predicting treatment efficacy. Although there(More)
Purpose: To find out Linnea's (a typical elderly citizen) main problem in her contacts with caregivers and to improve the network between actors around Linnea so that she can feel safe and confident. Context: Health services for people with multiple health-problems are to a growing extent provided for in the caretakers own home. The responsibility for this(More)
Objective/Background: Reports on heart failure (HF) predictors are scarce. We assessed gender-specific HF predictors. Design: Preventive case-finding programme, register study. Methods: We examined 33,342 HF-free subjects, 32.7% women, included in Malmö Preventive Project. Mean inclusion age was 49.7±7.4 years for women and 43.7±6.6 years for men. Results:(More)
  • 1